Home / Psoriasis

Psoriasis

New Head-to-Head Data Show Taltz Superiority vs. Tremfya in Patients with Moderate to Severe Plaque Psoriasis

TORONTO, Oct. 10, 2019 (GLOBE NEWSWIRE) — Eli Lilly and Company presented detailed data at the 5th Annual Maui Derm NP+PA Fall meeting from the Phase 4 IXORA-R study, the first head-to-head (H2H) study between an IL-17A inhibitor and an IL-23/p19 inhibitor using the Psoriasis Area Severity Index (PASI) 100 …

Read More »

Janssen Seeks FDA Approval of Stelara for the Treatment of Pediatric Patients with Moderate to Severe Plaque Psoriasis

SPRING HOUSE, Pa., Oct. 7, 2019  — The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) seeking expanded approval of STELARA® (ustekinumab) to treat pediatric (ages 6-11) patients with moderate to severe plaque psoriasis …

Read More »

Janssen Submits sBLA to the FDA Seeking Approval of Tremfya for Treatment of Adult Patients with Active Psoriatic Arthritis

HORSHAM, Pa., Sept. 16, 2019 /PRNewswire/ — The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) seeking first-in-class approval of TREMFYA® (guselkumab) for the treatment of adult patients with active psoriatic arthritis …

Read More »

Amgen to Acquire Celgene’s Psoriasis Drug Otezla for $13.4 Billion in Cash

THOUSAND OAKS, Calif., Aug. 26, 2019 /PRNewswire/ — Amgen (NASDAQ: AMGN) announced today that it has entered into an agreement with Celgene Corporation (NASDAQ: CELG) in connection with its previously announced merger with Bristol-Myers Squibb Company (NYSE: BMY) to acquire worldwide rights to Otezla® (apremilast), the only oral, non-biologic treatment for psoriasis and psoriatic arthritis, and certain related assets …

Read More »

Lilly’s Taltz Demonstrates Superiority Over Tremfya in Head-to-Head Trial in Patients with Moderate to Severe Plaque Psoriasis

INDIANAPOLIS, Aug. 13, 2019 /PRNewswire/ — Eli Lilly and Company(NYSE: LLY) announced today Taltz® (ixekizumab) met the primary and all major secondary endpoints up to week 12 in the Phase 4 IXORA-R study, which evaluated the efficacy and safety of Taltz versus TREMFYA®(guselkumab) in people living with moderate to severe plaque psoriasis (PsO). The …

Read More »

Leo Pharma Acquires Expanded Global Rights to Develop and Market Brodalumab for Moderate-to-Severe Psoriasis

BALLERUP, Denmark–(BUSINESS WIRE)–LEO Pharma A/S, a global leader in medical dermatology, today announced it has acquired the exclusive rights to develop and market brodalumab (marketed as Kyntheum® in the European Union) for the treatment of moderate-to-severe psoriasis outside of Europe through a new sub-licencing agreement with Bausch Health Ireland Limited. The …

Read More »

FDA Expands Approval of Leo Pharma’s Enstilar Foam and Taclonex Topical Suspension in Treatment of Plaque Psoriasis

MADISON, N.J.–(BUSINESS WIRE)–LEO Pharma Inc., a wholly owned subsidiary of LEO Pharma A/S, announced today the U.S. Food and Drug Administration (FDA) has expanded the approved indication for Enstilar® (calcipotriene and betamethasone dipropionate) Foam, 0.005%/0.064%, for the topical treatment of plaque psoriasis to include patients age 12 and older. The FDA …

Read More »

FDA Approves Samsung Bioepis’ Hadlima, a Biosimilar Referencing Humira

INCHEON, Korea–(BUSINESS WIRE)–Samsung Bioepis Co., Ltd. today announced that the US Food and Drug Administration (FDA) has approved HADLIMA™ (adalimumab-bwwd), a biosimilar referencing HUMIRA® i (adalimumab), for the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult Crohn’s disease, ulcerative colitis and plaque psoriasis. Please see below the …

Read More »

Janssen Reports Top-Line Phase 3 Results for Tremfya in Adults with Active Psoriatic Arthritis

HORSHAM, Pa.–(BUSINESS WIRE)–The Janssen Pharmaceutical Companies of Johnson & Johnson today announced top-line results from the Phase 3 DISCOVER 1 and 2 studies, which evaluated the efficacy and safety of guselkumab compared to placebo in adult patients with active moderate to severe psoriatic arthritis (PsA). Both studies met their primary …

Read More »

First-of-its-Kind Data Shows Efficacy and Safety of Novartis’ Cosentyx in All Key Manifestations of Psoriatic Arthritis

Basel, June 12, 2019 – Novartis, a leader in rheumatology and immuno-dermatology, today announced new data from the MAXIMISE trial evaluating the efficacy and safety of Cosentyx (secukinumab) in the management of axial manifestations of psoriatic arthritis (PsA). The ongoing 52-week Phase IIIb trial met both its primary and key secondary …

Read More »